Surgical robotics company eCential Robotics has appointed a new chief executive officer, Clément Vidal.
Surgical Robotics Company Names New CEO
1 min read Premium comments
Secondary#clementvidal#ecentialrobotics#endocontrol
Vidal has been with eCential Robotics since 2020, serving as business unit director. An Ecole Polytechnique and Stanford University graduate, Vidal has over 20 years of experience in the medical technology industry.
Vidal has been both an executive and entrepreneur. Prior to joining eCential Robotics he was director of site operations at France-based US Medical Innovations, LLC. Before that role, he spent nearly 15 years with France-based ENDOCONTROL. As ENDOCONTROL founder and CEO, Vidal was focused on the development and commercialization of robotic systems for laparoscopic surgery.
Vidal commented, “I am honored to take on the role of CEO at such an exciting time for the company.”
Vidal continued, “The team recently demonstrated its ability to successfully partner with MedTech companies, as well as commercialize our proprietary robotics system by signing a supply contract with a major healthcare group in the United States.”
Vidal takes the reins from founder Stéphane Lavallée. Lavallée will remain with the company serving as non-executive chairman of the board.
In the press release Lavallée expressed confidence in the new appointment, stating, “Through his excellent management of key strategic development programs within eCential Robotics, Clément has proven himself to be not only an amazing leader, but a visionary with a solid understanding of the surgical robotics market.”
Lavallée continued, “I am most confident that Clément will succeed in taking the company to the next level, with the same passion and commitment to innovation that has always been our hallmark.”
Based in Grenoble, France, eCential Robotics has created a system that brings together 2D/3D robotic imaging and surgical navigation for spine surgery. Its system, per the press release, is an “open, unified yet modular and scalable 2D/3D imaging, navigation, and robotic platform.” Since its founding in 2009, the company has hit a number of significant milestones including partnerships, FDA 510(k) clearance, awards, and funding.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.